COP化学療法プロトコル
**COPプロトコル**（シクロホスファミド、ビンクリスチン、プレドニゾロン）は、主にリンパ腫の治療に使用される獣医腫瘍学において一般的な多剤併用細胞毒性療法です。 > **臨床的警告：** ビンクリスチンは強力な発泡薬（壊死性抗がん剤）です。血管外漏出は重度の組織壊死を引き起こします。 **臨床のポイント：** 多くの腫瘍科医はCHOPプロトコルを好みますが、高用量COPは一般診療においても非常に有用で比較的実施しやすいプロトコルです。
作用機序: The COP protocol utilizes three distinct mechanisms to target neoplastic cells: * **Cyclophosphamide**: An alkylating agent that cross-links DNA strands → prevents DNA replication and transcription → induces cell death. * **Vincristine**: Binds to **tubulin** → inhibits microtubule formation and mitotic spindle assembly → arrests cell division in metaphase. * **Prednisolone**: A glucocorticoid that binds to specific intracellular receptors → alters gene expression → induces apoptosis in neoplastic lymphocytes.
動物種別の用量
- COP Protocol - Induction (Cyclophosphamide) · 250 mg/m2 · PO · q21d · First 6 months · Administer with Furosemide to prevent haemorrhagic cystitis.
- COP Protocol - Induction (Vincristine) · 0.70 mg/m2 · IV · q7d for 4 weeks, then q21d · First 6 months · On q21d schedule, give on the same day as cyclophosphamide.
- COP Protocol - Induction (Prednisolone) · 2 mg/kg (week 1), 1.5 mg/kg (week 2), 1 mg/kg (week 3), 1 mg/kg thereafter · PO · q24h (weeks 1-3), then q48h · First 6 months · Tapering dose schedule.
- COP Protocol - Adjunct (Furosemide) · 1 mg/kg · PO · q12h · For 48h (4 doses) concurrent with cyclophosphamide · Administered to promote diuresis and reduce risk of haemorrhagic cystitis.
- COP Protocol - Maintenance after 6 months (Cyclophosphamide) · 250 mg/m2 · PO · q28d · Months 6 to 12 · Stop protocol after 12 months and monitor for relapse.
- COP Protocol - Maintenance after 6 months (Vincristine) · 0.70 mg/m2 · IV · q28d · Months 6 to 12 · Administer with cyclophosphamide.
- COP Protocol - Maintenance after 6 months (Prednisolone) · 1 mg/kg · PO · q48h · Months 6 to 12 · Stop protocol after 12 months and monitor for relapse.
- Alternative to Cyclophosphamide (Chlorambucil) · 20 mg/m2 · PO · As directed replacing cyclophosphamide · Ongoing · Use if haemorrhagic cystitis develops or if blood is noted on urine dipstick and culture is negative.
用量は獣医療従事者向けの臨床リファレンスです。必ず最新の添付文書と個々の患者で確認してください。
投与経路
禁忌
- Severe neutropenia (< 2 x 10^9/L)
- Pre-existing haemorrhagic cystitis
- Known MDR1 mutation (requires extreme caution/dose adjustment for vincristine)
有害事象
- Myelosuppression (neutropenia)
- Haemorrhagic cystitis (cyclophosphamide)
- Gastrointestinal toxicity (vomiting, diarrhoea, anorexia)
- Tissue necrosis if extravasated (vincristine)
薬物相互作用
- Cimetidine · Inhibits hepatic cytochrome P450 enzyme pathway, potentially altering the metabolism and increasing toxicity of chemotherapeutics. · major
モニタリング
- Haematology (prior to each vincristine treatment)
- Biochemistry (prior to first treatment, then minimum every 6 months)
- Free-catch urine dipstick (prior to each cyclophosphamide administration to check for blood)
- Urine culture (if blood is noted on dipstick)
過量投与
**Severe toxicity:** Overdose of these chemotherapeutics can lead to fatal myelosuppression, severe gastrointestinal sloughing, sepsis, and death. Extravasation of vincristine causes severe, progressive tissue necrosis requiring immediate management (e.g., hyaluronidase, warm compresses).
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。